{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T01:56:59Z","timestamp":1775181419784,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T00:00:00Z","timestamp":1476662400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s10198-016-0837-7","type":"journal-article","created":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T11:39:41Z","timestamp":1476704381000},"page":"937-965","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic review of cost-effectiveness studies"],"prefix":"10.1007","volume":"18","author":[{"given":"Alexandre","family":"Baptista","sequence":"first","affiliation":[]},{"given":"In\u00eas","family":"Teixeira","sequence":"additional","affiliation":[]},{"given":"S\u00f3nia","family":"Romano","sequence":"additional","affiliation":[]},{"given":"Ant\u00f3nio Vaz","family":"Carneiro","sequence":"additional","affiliation":[]},{"given":"Julian","family":"Perelman","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2016,10,17]]},"reference":[{"key":"837_CR1","unstructured":"International Diabetes Federation. IDF Diabetes atlas, 7th edition. Brussels, Belgium: International Diabetes Federation, 2015. http:\/\/www.diabetesatlas.org . Accessed 20 Apr 2016"},{"key":"837_CR2","volume-title":"Diabetes expenditure, burden of disease and management in 5 EU countries","author":"P Kanavos","year":"2012","unstructured":"Kanavos, P., Aardweg, S., Schurer, W.: Diabetes expenditure, burden of disease and management in 5 EU countries. LSE Health, London School of Economics, London (2012)"},{"key":"837_CR3","unstructured":"American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013. http:\/\/care.diabetesjournals.org\/content\/early\/2013\/03\/05\/dc12-2625.full.pdf . Accessed 20 Apr 2016"},{"key":"837_CR4","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2337\/dc14-2441","volume":"38","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A.L., Tsapas, A., Wender, R., Matthews, D.R.: Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care 38, 140\u2013149 (2015). doi: 10.2337\/dc14-2441","journal-title":"Diabetes Care"},{"key":"837_CR5","doi-asserted-by":"crossref","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","volume":"151","author":"A Liberati","year":"2009","unstructured":"Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., G\u00f8tzsche, P.C., Ioannidis, J.P.A., Clarke, M., Devereaux, P.J., Kleijnen, J., Moher, D.: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann. Int. Med. 151, W65\u2013W94 (2009)","journal-title":"Ann. Int. Med."},{"key":"837_CR6","volume-title":"Systematic reviews. CRD\u2019s guidance for undertaking reviews in healthcare","author":"Centre for Reviews and Dissemination","year":"2008","unstructured":"Centre for Reviews and Dissemination: Systematic reviews. CRD\u2019s guidance for undertaking reviews in healthcare. CRD University of York, York (2008)"},{"key":"837_CR7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1136\/bmj.313.7052.275","volume":"313","author":"M Drummond","year":"1996","unstructured":"Drummond, M., Jefferson, T.: Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 313, 275\u2013283 (1996)","journal-title":"BMJ"},{"key":"837_CR8","unstructured":"World Bank. World Bank Country and Lending Groups Data. https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519#High_income (2016). Accessed 6 Jul 2016"},{"key":"837_CR9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1524-4733.2009.00663.x","volume":"13","author":"J Hay","year":"2010","unstructured":"Hay, J., Smeeding, J., Carrol, N.V., Drummond, M., Garrison, L.P., Mansley, E.C., Mullins, C.D., Mycka, J.M., Seal, B., Shi, L.: Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report\u2014part I. Value Health 13, 3\u20137 (2010)","journal-title":"Value Health"},{"key":"837_CR10","volume-title":"Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health","author":"JD Sachs","year":"2003","unstructured":"Sachs, J.D.: Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. World Health Organization, Geneva (2003)"},{"key":"837_CR11","volume-title":"Making choices in health: WHO guide to cost-effectiveness analysis","author":"RMPM Baltussen","year":"2003","unstructured":"Baltussen, R.M.P.M., Adam, T., Tan-Torres, E.T., Hutubessy, R.C.W., Acharya, A., Evans, D.B., Murray, C.J.L.: Making choices in health: WHO guide to cost-effectiveness analysis. World Health Organization, Geneva (2003)"},{"issue":"Supplement 1","key":"837_CR12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1463-1326.2008.00886.x","volume":"10","author":"B Schwarz","year":"2008","unstructured":"Schwarz, B., Gouveia, M., Chen, J., Nocea, G., Jameson, K., Cook, J., Krishnarajah, G., Alemao, E., Yin, D., Sintonen, H.: Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. Diabetes Obes. Metab. 10(Supplement 1), 43\u201355 (2008)","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"837_CR13","first-page":"13","volume":"7","author":"R Pereira","year":"2012","unstructured":"Pereira, R., Gouveia, M., Martins, A.P.: An\u00e1lise custo-efectividade de sitagliptina quando adicionada a metformina em doentes com diabetes tipo 2 em Portugal. Revista Portuguesa de diabetes 7(1), 13\u201323 (2012)","journal-title":"Revista Portuguesa de diabetes"},{"issue":"1","key":"837_CR14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/2191-1991-3-11","volume":"3","author":"JF Elgart","year":"2013","unstructured":"Elgart, J.F., Caporale, J.E., Gonzalez, L., Aiello, E., Waschbusch, M., Gagliardino, J.J.: Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina. Health Econ. Rev. 3(1), 11 (2013)","journal-title":"Health Econ. Rev."},{"issue":"3","key":"837_CR15","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/11597060-000000000-00000","volume":"32","author":"W Erhardt","year":"2012","unstructured":"Erhardt, W., Bergenheim, K., Duprat-Lomon, I., McEwan, P.: Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff Diabetes Model analysis. Clin. Drug Investig. 32(3), 189\u2013202 (2012)","journal-title":"Clin. Drug Investig."},{"issue":"2","key":"837_CR16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.pcd.2011.09.003","volume":"6","author":"O Granstrom","year":"2012","unstructured":"Granstrom, O., Bergenheim, K., McEwan, P., Sennfalt, K., Henriksson, M.: Cost-effectiveness of saxagliptin (Onglyza) in type 2 diabetes in Sweden. Primary Care Diabetes 6(2), 127\u2013136 (2012)","journal-title":"Primary Care Diabetes"},{"issue":"1","key":"837_CR17","first-page":"20","volume":"4","author":"K Bergenheim","year":"2012","unstructured":"Bergenheim, K., Williams, S.A., Bergeson, J.G., Stern, L., Sriprasert, M.: US cost-effectiveness of saxagliptin in type 2 diabetes mellitus. Am. J. Pharm. Benefits 4(1), 20\u201328 (2012)","journal-title":"Am. J. Pharm. Benefits"},{"issue":"2","key":"837_CR18","first-page":"60","volume":"9","author":"D Carvalho","year":"2014","unstructured":"Carvalho, D., Contente, M., Silva, C., Trindade, R.: Saxagliptin in the treatment of diabetes mellitus type 2 in Portugal: a study of cost-utility in the perspective of society. Revista Portuguesa da Diabetes 9(2), 60\u201372 (2014)","journal-title":"Revista Portuguesa da Diabetes"},{"issue":"1","key":"837_CR19","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1089\/dia.2011.0092","volume":"14","author":"W Grzeszczak","year":"2012","unstructured":"Grzeszczak, W., Czupryniak, L., Kolasa, K., Sciborski, C., Lomon, I.D., McEwan, P.: The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland. Diabetes Technol. Therap. 14(1), 65\u201373 (2012)","journal-title":"Diabetes Technol. Therap."},{"issue":"3","key":"837_CR20","first-page":"294","volume":"58","author":"ME Nita","year":"2011","unstructured":"Nita, M.E., Eliaschewitz, F.G., Ribeiro, E., Asano, E., Barbosa, E., Takemoto, M., Donato, B., Rached, R., Rahal, E.: Cost-effectiveness and budget impact of saxagliptin as additional therapy to metformin for the treatment of diabetes mellitus type 2 in the Brazilian private health system. Rev. Assoc. Med. Bras. 58(3), 294\u2013301 (2011)","journal-title":"Rev. Assoc. Med. Bras."},{"issue":"7","key":"837_CR21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3111\/13696998.2014.912986","volume":"17","author":"D Viriato","year":"2014","unstructured":"Viriato, D., Calado, F.; Gruenberger, J.B., Ong, S.H., Carvalho, D., Silva-Nunes, J., Johal, S., Viana, R.: Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective. J. Med. Econ. 17(7), 499\u2013507 (2014)","journal-title":"J. Med. Econ."},{"issue":"2","key":"837_CR22","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s13300-014-0084-9","volume":"5","author":"Q Li","year":"2014","unstructured":"Li, Q., Chitnis, A., Hammer, M., Langer, J.: Real-world clinical and economic outcomes of liraglutide versus sitagliptin in patients with type 2 diabetes mellitus in the United States. Diabetes Ther. 5(2), 579\u2013590 (2014)","journal-title":"Diabetes Ther."},{"issue":"9","key":"837_CR23","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3111\/13696998.2014.933110","volume":"17","author":"KS Carlsson","year":"2014","unstructured":"Carlsson, K.S., Persson, U.: Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagliptin J. Med. Econ. 17(9), 658\u2013669 (2014). doi: 10.3111\/13696998.2014.933110 . (Epub 2014 Jun 26)","journal-title":"Med. Econ."},{"key":"837_CR24","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/1472-6963-14-419","volume":"14","author":"C Tzanetakos","year":"2014","unstructured":"Tzanetakos, C., Melidonis, A., Verras, C., Kourlaba, G., Maniadakis, N.: Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugs in Greece. BMC Health Serv. Res. 14, 419 (2014)","journal-title":"BMC Health Serv. Res."},{"issue":"3","key":"837_CR25","doi-asserted-by":"crossref","first-page":"237","DOI":"10.18553\/jmcp.2013.19.3.237","volume":"19","author":"J Langer","year":"2013","unstructured":"Langer, J., Hunt, B., Valentine, W.J.: Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States. J Manag. Care Pharm. 19(3), 237\u2013246 (2013)","journal-title":"J Manag. Care Pharm."},{"key":"837_CR26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s13300-015-0103-5","volume":"6","author":"A Perez","year":"2015","unstructured":"Perez, A., Raya, P.M., Arellano, A.R., Briones, T., Hunt, B., Valentine, W.J.: Cost-effectiveness analysis of incretin therapy for type 2 diabetes in Spain:1.8 mg liraglutide vs. sitagliptin. Diabetes Ther. 6, 61\u201374 (2015)","journal-title":"Diabetes Ther."},{"key":"837_CR27","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s13300-013-0044-9","volume":"4","author":"PM Raya","year":"2013","unstructured":"Raya, P.M., Perez, A., Arellano, A.R., Briones, T., Hunt, B., Valentine, W.J.: Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin. Diabetes Ther. 4, 417\u2013430 (2013)","journal-title":"Diabetes Ther."},{"issue":"3","key":"837_CR28","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1464-5491.2011.03429.x","volume":"29","author":"MJ Davies","year":"2012","unstructured":"Davies, M.J., Chubb, B.D., Smith, I.C., Valentine, W.J.: Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in type 2 diabetes mellitus. Diabet. Med. 29(3), 313\u2013320 (2012)","journal-title":"Diabet. Med."},{"issue":"Supplement 2","key":"837_CR29","first-page":"28","volume":"15","author":"WC Lee","year":"2012","unstructured":"Lee, W.C., Samyshkin, Y., Langer, J., Palmer, J.L.: Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE diabetes model analysis. J. Med. Econ. 15(Supplement 2), 28\u201337 (2012)","journal-title":"J. Med. Econ."},{"issue":"11","key":"837_CR30","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.clinthera.2014.07.019","volume":"36","author":"ST Brown","year":"2014","unstructured":"Brown, S.T., Grima, D.G., Sauriol, L.: Cost-effectiveness of insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus. Clin. Ther. 36(11), 1576\u20131587 (2014)","journal-title":"Clin. Ther."},{"key":"837_CR31","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s13300-014-0080-0","volume":"5","author":"AA Kiadaliri","year":"2014","unstructured":"Kiadaliri, A.A., Gerdtham, U.G., Eliasson, B., Carlsson, K.S.: Cost-utility analysis of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn basal insulin as add-on to metformin in type 2 diabetes in Sweden. Diabetes Ther. 5, 591\u2013607 (2014)","journal-title":"Diabetes Ther."},{"issue":"47","key":"837_CR32","first-page":"1747","volume":"10","author":"J Chen","year":"2008","unstructured":"Chen, J., Alemao, E., Yin, D., Cook, J.: Development of a diabetes treatment simulation model: with application to assessing alternative treatment intensification strategies on survival and diabetes related complications. Diabetes Obes. Metab. 10(47), 1747\u20131759 (2008)","journal-title":"Diabetes Obes. Metab."},{"key":"837_CR33","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s00125-004-1527-z","volume":"47","author":"PM Clarke","year":"2004","unstructured":"Clarke, P.M., Gray, A.M., Briggs, A., Farmer, A.J., Fenn, P., Stevens, R.J., Matthews, D.R., Stratton, I.M., Holman, R.R.: A model to estimate the lifetime health outcomes of patients with diabetes type 2: the United Kingdom prospective diabetes study (UKPDS) outcomes model (UKPDS no.68). Diabetologia 47, 1747\u20131759 (2004)","journal-title":"Diabetologia"},{"issue":"4","key":"837_CR34","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jval.2013.01.002","volume":"16","author":"AJ Palmer","year":"2013","unstructured":"Palmer, A.J., Mount Hood 5 Modeling Group.: Computer modeling of diabetes and its complications: a report on the fifth Mount Hood challenge meeting. Value Health 16(4), 670\u2013685 (2013)","journal-title":"Value Health"},{"key":"837_CR35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1185\/030079906X80350","volume":"22","author":"P McEwan","year":"2006","unstructured":"McEwan, P., Peters, J.R., Bergenheim, K., Currie, C.J.: Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). Curr. Med. Res. Opin. 22, 121\u2013129 (2006)","journal-title":"Curr. Med. Res. Opin."},{"key":"837_CR36","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2165\/11535350-000000000-00000","volume":"28","author":"P McEwan","year":"2010","unstructured":"McEwan, P., Bergenheim, K., Yuan, Y., Tetlow, A.P., Gordon, J.P.: Assessing the relationship between computational speed and precision: a case study comparing an interpreted versus compiled programming language using a stochastic simulation model in healthcare. Pharmacoeconomics 28, 665\u2013674 (2010)","journal-title":"Pharmacoeconomics"},{"issue":"1 Suppl","key":"837_CR37","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1185\/030079904X1980","volume":"20","author":"AJ Palmer","year":"2004","unstructured":"Palmer, A.J., Roze, S., Valentine, W.J., Minshall, M.E., Foos, V., Lurati, F.M., Lammert, M., Spinas, G.A.: The core diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr. Med. Res. Opin. 20(1 Suppl), S5\u2013S26 (2004)","journal-title":"Curr. Med. Res. Opin."},{"key":"837_CR38","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1742-1241.2011.02656.x","volume":"65","author":"R Pratley","year":"2011","unstructured":"Pratley, R., Nauck, M., Bailey, T., Montanya, E., Cuddihy, R., Filetti, S., Garber, A., Thomses, A.B., Hartvig, H., Davies, M.: One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int. J. Clin. Pract. 65, 397\u2013407 (2011)","journal-title":"Int. J. Clin. Pract."},{"key":"837_CR39","unstructured":"OECD. OECD.Stat. https:\/\/stats.oecd.org\/Index.aspx?DataSetCode=PDB_LV## (2015). Accessed 29 Jun 2016"},{"issue":"36","key":"837_CR40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta14360","volume":"14","author":"N Waugh","year":"2010","unstructured":"Waugh, N., Cummins, E., Royle, P., Clar, C., Marien, M., Richter, B., Philip, S.: Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol. Assess. 14(36), 1\u2013248 (2010)","journal-title":"Health Technol. Assess."},{"key":"837_CR41","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40273-015-0266-y","volume":"33","author":"J Geng","year":"2015","unstructured":"Geng, J., Yu, H., Ma, O.Y., Zhang, P., Chen, Y.: Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Pharmacoeconomics 33, 581\u2013597 (2015)","journal-title":"Pharmacoeconomics"},{"key":"837_CR42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11892-016-0744-4","volume":"16","author":"V Ahuja","year":"2016","unstructured":"Ahuja, V., Chou, C.H.: Novel therapeutics for diabetes: uptake, usage trends, and comparative effectiveness. Curr. Diabetes Rep. 16, 47 (2016)","journal-title":"Curr. Diabetes Rep."},{"issue":"7543","key":"837_CR43","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/bmj.38737.607558.80","volume":"332","author":"CH Bell","year":"2006","unstructured":"Bell, C.H., Urbach, D.R., Ray, J.G., Bayoumi, A., Rosen, A.B., Greenberg, D., Neumann, P.J.: Bias in published cost effectiveness studies: systematic review. BMJ 332(7543), 699\u2013703 (2006)","journal-title":"BMJ"},{"issue":"4","key":"837_CR44","doi-asserted-by":"publisher","first-page":"985","DOI":"10.2337\/dc13-2097","volume":"37","author":"LW Turner","year":"2014","unstructured":"Turner, L.W., Nartey, D., Stafford, R.S., Singh, S., Alexander, G.C.: Ambulatory treatment of type 2 diabetes in the U.S., 1997\u20132012. Diabetes Care 37(4), 985\u2013992 (2014). doi: 10.2337\/dc13-2097","journal-title":"Diabetes Care"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10198-016-0837-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-016-0837-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-016-0837-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T14:34:16Z","timestamp":1657463656000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10198-016-0837-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,17]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["837"],"URL":"https:\/\/doi.org\/10.1007\/s10198-016-0837-7","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,17]]}}}